Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks Investment Research9/1/2026Positive
ONC
BeiGene, Ltd.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$40.53B
P/E Ratio
64.09
EPS
$5.59
Beta
0.52
52W High
$385.22
52W Low
$253.95
50-Day MA
$333.59
200-Day MA
$317.91
Dividend Yield
—
Profit Margin
10.70%
Forward P/E
34.97
PEG Ratio
0.77
About BeiGene, Ltd.
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Fundamentals
| Revenue (TTM) | $6.13B |
| Gross Profit (TTM) | $5.45B |
| EBITDA | $1.07B |
| Operating Margin | 19.10% |
| Return on Equity | 14.70% |
| Return on Assets | 7.46% |
| Revenue/Share (TTM) | $55.27 |
| Book Value | $45.78 |
| Price-to-Book | 7.93 |
| Price-to-Sales (TTM) | 6.61 |
| EV/Revenue | 6.26 |
| EV/EBITDA | 33.69 |
| Quarterly Earnings Growth (YoY) | 166.70% |
| Quarterly Revenue Growth (YoY) | 29.60% |
| Shares Outstanding | $104.27M |
| Float | $80.95M |
| % Insiders | 17.28% |
| % Institutions | 33.12% |
Historical Volatility
HV 10-Day
16.19%
HV 20-Day
27.86%
HV 30-Day
30.35%
HV 60-Day
28.36%
HV Rank
16.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($432.16 target)
8
Strong Buy20
BuyLatest News
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com. An archived webcast will be available on the Company's website. About BeOne Medicin.
Business Wire9/1/2026Neutral
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scien.
Business Wire8/31/2026Neutral
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonst.
Business Wire8/31/2026Neutral
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?
Zacks Investment Research8/27/2026Positive
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective.
Zacks Investment Research8/25/2026Positive
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with.
Business Wire8/18/2026Neutral
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.
Business Wire8/10/2026Neutral
BeOne Medicines Q2 Earnings Call Highlights
BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued to expand across approved indications and global markets.
MarketBeat8/5/2026Positive
BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript
BeOne Medicines AG (ONC) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ONC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026